In the second study, 599 patients with stage IIIB or IV disease were randomised to receive cisplatin (75 mg/ m2) and etoposide (100 mg/ m2; n= 200), or cisplatin (75 mg/ m2) and low-dose paclitaxel (135 mg/ m2; n= 198), or cisplatin (75 mg/ m2) and high-dose paclitaxel (250 mg/ m2) with G-CSF (n= 201).